Please refer to attachment.

Profit growth above 25%EBITDA margin expansionExceptional itemResults View source PDF Explain this filing

INDIAGLYCO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.4%Reaction day

₹1085.00

prior close

₹1065.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%-6.0% vs market

Breweries & Distilleries peers, median of 25sector-1.1%-5.2% vs sector

On the reaction day the stock moved 6.0 pts less than Nifty Microcap 250 and 5.2 pts less than its Breweries & Distilleries peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.0

10m

-2.9

15m

-3.4

30m

-2.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.4-0.4-6.0-1.1-5.2

Next day

-6.8-1.7-5.1-2.5-4.3

-8.0-1.3-6.7-2.7-5.3

-8.4-0.7-7.7-2.7-5.6

-8.6+0.4-9.0-3.5-5.1

-9.2+0.5-9.7-3.7-5.5

-7.1+2.8-9.9-1.8-5.3

15d

-10.1+1.2-11.3-4.3-5.8

-10.0+5.3-15.4-2.1-7.9

+5.1+9.9-4.8-3.9+8.9

-1.6+13.1-14.7-5.4+3.8

UpDownMarket · Nifty Microcap 250Sector · Breweries & Distilleries peers, median of 25Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

India Glycols Limited reported strong FY2026 results with standalone PAT growing 56.5% to Rs 282.33 crore from Rs 180.38 crore in FY2025. Revenue from operations increased 8.7% to Rs 9,826.20 crore. EBITDA rose 32.4% to Rs 690.09 crore with margin expansion of approximately 168 basis points. The company completed a preferential issue raising Rs 467 crore in November 2025, and a stock split was executed in August 2025 (face value reduced from Rs 10 to Rs 5). A demerger scheme for the Bio Pharma and Spirits & Biofuel undertaking is pending NCLT approval with next hearing on May 21, 2026. Auditors issued an unmodified (clean) opinion on both standalone and consolidated financial statements.

Likely market impact

The company delivered robust profit growth well above the 25% threshold with EBITDA margin expansion, indicating improved operational efficiency. The Rs 467 crore capital raise strengthens the balance sheet. The pending demerger could unlock value for shareholders if approved by NCLT.